Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 45

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 45
---
N-820 during a specified period. • With respect to Mr. Dec: • Exceed non-GAAP operating earnings or net product sales guidance issued by the Company at the beginning of the year by a specified percentage for 2024 and 2025 combined; • Simplify and optimize corporate structure to improve net effective corporate tax in 2025; • Lead the project of improving certain expenses by a specified percentage from the 2024 budget by 2025 • Establish a specific database and software to monitor and manage certain activities no later than a specified period; and • Secure financing for a Corporate Development Transaction. • With respect to Dr. Rubin: • Generate a new compound hit from the new discovery platform by December 2025; • First in human study for a new program with first patient first visit by a specified period; • Finalize Integrated Development Plan for a specific program including a clear strategy for creating intellectual property and a well differentiated product profile by end of 2024; and • Achieve positive Phase II data on SPN-820 during a specified period. • With respect to Dr. Bhatt: • Finalize Integrated Development Plan for a specific program with certain specified criteria by the end of 2024; • File a new patent application for one of the new chemical entities from the discovery platform in 2027; and • Issuance of a new patent for one of the new chemical entities from the discovery platform by 2028. • With respect to Mr. Mottola: • Obtain approval from the FDA of SPN-830 no later than a specified period; • Manage IT through 2026 such that any cyber-attack on the Company’s systems and network does not disrupt business continuity for more than a specified period; and • Finalize Integrated Development Plan for a specific program with certain specified criteria by the end of 2024. Restricted Stock Units The Company’s restricted stock units (“RSU”) awards vest in four equal installments of 25% each on the first four anniversaries of the date of grant provided the NEO continues to serve at Supernus on each 29 such anniversary date. The Board of Directors believes that providing NEOs (other than the CEO) a mix of time-vesting and performance-vesting equity awards based on pre-established goals achieves a balance in our equity-based compensation program and further aligns the interests of such officer and our stockholders through the RSU award’s retention value. In connection with the foregoing, on February 22, 2024, Mr